759,971 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by Legal & General Group Plc

Legal & General Group Plc acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 759,971 shares of the biopharmaceutical company’s stock, valued at approximately $473,872,000.

Several other large investors also recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $5,682,636,000. Dodge & Cox increased its position in shares of Regeneron Pharmaceuticals by 1.0% during the 4th quarter. Dodge & Cox now owns 4,596,358 shares of the biopharmaceutical company’s stock valued at $3,547,791,000 after purchasing an additional 45,513 shares during the last quarter. Franklin Resources Inc. raised its holdings in Regeneron Pharmaceuticals by 4.4% during the 4th quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock valued at $1,975,990,000 after buying an additional 106,861 shares during the period. Nuveen LLC raised its holdings in Regeneron Pharmaceuticals by 71.1% during the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock valued at $1,551,858,000 after buying an additional 835,240 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its position in Regeneron Pharmaceuticals by 142.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock worth $1,504,991,000 after buying an additional 1,144,887 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $320,000.00. Following the transaction, the director owned 603 shares of the company’s stock, valued at approximately $482,400. This trade represents a 39.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This represents a 31.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,400 shares of company stock worth $1,090,030 in the last three months. Corporate insiders own 6.97% of the company’s stock.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: An analysis titled “Regeneron: Why I Still See Upside After the Rally” reflects a continued bullish view of REGN’s long-term prospects following its recent advance. Regeneron: Why I Still See Upside After the Rally
• Neutral Sentiment: Reported short-interest data showed zero shares short and a zero-day short-interest ratio. However, the figures appear incomplete or erroneous, making them unsuitable as a meaningful trading signal.
• Negative Sentiment: Several law firms publicized a securities-fraud class action tied to Regeneron’s Phase 3 melanoma-therapy trial failure. The trial disclosure reportedly triggered a sharp selloff and erased approximately $11 billion in market value; the lawsuit alleges investors were harmed by inadequate or misleading disclosures. A September 14, 2026 deadline applies to investors seeking lead-plaintiff status. Notices were issued by Hagens Berman, Pomerantz, SueWallSt, and Portnoy Law.
• Negative Sentiment: Additional law firms, including Faruqi & Faruqi, Schall Brown & Schwartz, and Levi & Korsinsky, reiterated the pending litigation and encouraged affected shareholders to participate. The repeated announcements increase near-term legal and reputational overhang, although they do not represent new operating developments. Faruqi & Faruqi notice

Analysts Set New Price Targets

Several research analysts have commented on REGN shares. Benchmark raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a research note on Tuesday, July 7th. HSBC reduced their target price on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research note on Monday, July 6th. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 15th. Sanford C. Bernstein upgraded shares of Regeneron Pharmaceuticals to a “hold” rating in a report on Wednesday, July 29th. Finally, Morgan Stanley upped their price target on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. Sixteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $801.70.

Regeneron Pharmaceuticals Stock Up 0.6%

Shares of NASDAQ:REGN opened at $833.56 on Wednesday. The business’s 50 day moving average is $705.74 and its 200 day moving average is $717.35. The stock has a market cap of $85.82 billion, a P/E ratio of 20.60, a price-to-earnings-growth ratio of 1.41 and a beta of 0.22. Regeneron Pharmaceuticals, Inc. has a 52-week low of $541.00 and a 52-week high of $847.00. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. During the same period in the previous year, the company posted $12.81 EPS. Regeneron Pharmaceuticals’s revenue was up 16.7% on a year-over-year basis. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.29%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.